Healthcare (Medical Licensing)

S 1830, the Right to Treat Act, prohibits federal agencies like the FDA from regulating the practice of medicine and bans restrictions on prescribing FDA-approved drugs for unapproved uses. It directly affects doctors, patients, and pharmaceutical companies by removing federal barriers to off-label drug prescriptions. The bill explicitly excludes federal laws related to abortion, assisted suicide, euthanasia, or gender transition medical interventions from its scope. This is a procedural change to federal regulatory authority, not a new program or funding measure.

This bill clarifies that states can use direct primary care arrangements under Medicaid, where patients pay a fixed monthly fee for primary care services (like check-ups and preventive care) instead of traditional billing. It directly affects Medicaid beneficiaries, primary care providers, and state Medicaid agencies by allowing states to contract with providers for this model through managed care organizations. Key provisions require the Health Secretary to issue implementation guidance within one year and submit a report to Congress within two years analyzing how states use these arrangements and their impact on care quality and costs. The bill does not change existing Medicaid requirements for cost-sharing or the scope of covered services.

This bill modifies requirements for approving biosimilar drugs (follow-on versions of biologic medicines). It removes previous mandatory assessments of immunogenicity or clinical efficacy for biosimilar licensure, instead allowing the FDA to require such studies only when the agency provides written justification to the applicant. The change applies to new biosimilar applications submitted after the bill's enactment. It directly affects drug manufacturers seeking FDA approval for biosimilars and the FDA's review process, aiming to streamline approvals while maintaining safety standards.